Review Article Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease
Whitney Wharton, Carey E. Gleason, Katelin R. Lorenze, Tamara S. Markgraf, Michele L. Ries, Cynthia M. Carlsson, Sanjay Asthana
Laboratory for Cancer Ontogeny and Therapeutics, Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
Received January 14, 2009; accepted January, 2009; available online January, 2009
Abstract: Over a decade of converging findings from clinical, observational and basic science research indicate that estrogen administration during the menopausal transition exerts beneficial effects on cognition and decreases a woman’s risk of developing Alzheimer’s disease (AD) later in life. This review article stresses the research focus of AD prevention, and introduces hormone therapy (HT) as a probable catalyst that may achieve this goal. Furthermore, this article outlines 3 mechanisms proposed to mediate estrogen’s beneficial effects, discusses the controversy surrounding HT administration, and presents the most promising estrogen related research in AD prevention and treatment. Although controversial, cumulative evidence suggests that the potential of estrogen initiated during perimenopause to prevent AD needs to be systematically evaluated. (AJTR901005).
Address all correspondence to: Whitney Wharton, Ph.D. University of Wisconsin School of Medicine and Public Health William S. Middleton VA Hospital 2500 Overlook Terrace, GRECC 11G Madison WI 53705 Phone: (608) 256-1901, ext. 11516 Email: firstname.lastname@example.org